/
CGTX
$1.03+$0.00 (+0.00%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$98.9M
95M shares
52-week range
$0.55 – $3.83
15% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-11.73
Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
www.cogrx.com- Employees
- 14
- IPO / List date
- Oct 8, 2021
- HQ
- PURCHASE, NY
Held by traders on TradeandTell
No one on the platform currently holds CGTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,117,136 | $848.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CGTX yet.
